<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141211">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879683</url>
  </required_header>
  <id_info>
    <org_study_id>TAR-100-105</org_study_id>
    <nct_id>NCT01879683</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC)and Hunner's Lesions</brief_title>
  <official_title>A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TARIS Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TARIS Biomedical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when
      administered to women with  Interstitial Cystitis with Hunner's lesions, and  to evaluate
      any change in the bladder or in IC symptoms, following LiRIS administration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in appearance of Hunner's Lesion.</measure>
    <time_frame>Study Day 14 or 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subject reported IC symptoms (bladder pain, urinary frequency)</measure>
    <time_frame>Screen (Day -5 to -1);  during treatment (Day 0 - 14) and on designated days during follow up period of 4 weeks after treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects rate symptom of bladder pain for 5 days during screening, daily during treatment (study days 0 to 14), and for 3 days prior to follow up visits at  1,2, and 4 weeks after treatment.  Subjects also record each daytime and night time void for 3 days during screening, and for 3 days prior to visits on study days 7 and 14, and the follow up visits at 1,2, and 4 weeks after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>LiRIS®  400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LiRIS® 400 mg</intervention_name>
    <description>LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the  bladder for  up to  14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.</description>
    <arm_group_label>LiRIS®  400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 18 and older

          -  Interstitial Cystitis with history of Hunner's lesions in the bladder

          -  Moderate to severe bladder discomfort

          -  Confirmation of Hunner's lesions in Bladder

          -  Able to report symptom (pain and voiding frequency) in a diary throughout the study

        Exclusion Criteria:

          -  Pregnant women

          -  History or presence of bladder cancer

          -  History or presence of any condition that would make it difficult to evaluate
             bladder symptoms
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>June 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hunner's lesion</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
